tbuckley/cabot-search huggingface dataset:
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes
Journal: Diabetes Care (2015)

OBJECTIVE Glycemic variability may contribute to adverse medical outcomes of type 2 diabetes, but prior therapies have had limited success in controlling glycemic fluctuations, and the hypothesis has not been adequately tested. RESEARCH DESIGN AND METHODS People with insulin-requiring type 2 diabetes and high cardiovascular risk were enrolled during a run-in period on basal-bolus insulin (BBI), and 102 were randomized to continued BBI or to basal insulin with a prandial GLP-1 receptor agonist (GLIPULIN) group, each seeking to maintain HbA1c levels between 6.7% and 7.3% (50–56 mmol/mol) for 6 months. The primary outcome measure was glycemic variability assessed by continuous glucose monitoring; other measures were HbA1c, weight, circulating markers of inflammation and cardiovascular risk, albuminuria, and electrocardiographic patterns assessed by Holter monitoring. RESULTS At randomization, the mean age of the population was 62 years, median duration of diabetes 15 years, mean BMI 34 kg/m2, and mean HbA1c 7.9% (63 mmol/mol). Thirty-three percent had a prior cardiovascular event, 18% had microalbuminuria, and 3% had macroalbuminuria. At baseline, the continuous glucose monitoring coefficient of variation for glucose levels was similar in both groups. CONCLUSIONS FLAT-SUGAR is a proof-of-concept study testing whether, in a population of individuals with type 2 diabetes and high cardiovascular risk, the GLIPULIN regimen can limit glycemic variability more effectively than BBI, reduce levels of cardiovascular risk markers, and favorably alter albuminuria and electrocardiographic patterns. We successfully randomized a population that has sufficient power to answer the primary question, address several secondary ones, and complete the protocol as designed.
THE DIAGNOSIS OF TWIN PREGNANCY.
Authors: E Kobata
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Invasive Cancer Incidence—United States, 2009
Authors: S Jane Henley, Simple Singh, Jessica King, Reda Wilson, Blythe Ryerson
Journal: JAMA (2013)

Cancer has many causes, some of which can, at least in part, be avoided through interventions known to reduce cancer risk. Healthy People 2020 objectives call for reducing colorectal cancer incidence to 38.6 per 100,000 persons, reducing late-stage breast cancer incidence to 41.0 per 100,000 women, and reducing cervical cancer incidence to 7.1 per 100,000 women. To assess progress toward reaching these Healthy People 2020 targets, CDC analyzed data from U.S. Cancer Statistics (USCS) for 2010. USCS includes incidence data from CDC's National Program of Cancer Registries and the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program and mortality data from the National Vital Statistics System. In 2010, a total of 1,456,496 invasive cancers were reported to cancer registries in the United States (excluding Arkansas and Minnesota), an annual incidence rate of 446 cases per 100,000 persons, compared with 459 in 2009. Cancer incidence rates were higher among men (503) than women (405), highest among blacks (455), and ranged by state from 380 to 511 per 100,000 persons. Many factors, including tobacco use, obesity, insufficient physical activity, and human papilloma virus (HPV) infection, contribute to the risk for developing cancer, and differences in cancer incidence indicate differences in the prevalence of these risk factors. These differences can be reduced through policy approaches such as the Affordable Care Act, which could increase access for millions of persons to appropriate and timely cancer preventive services, including help with smoking cessation, cancer screening, and vaccination against HPV.
The decision to hospitalize
Authors: E B Feigelson, E B Davis, R Mackinnon, H C Shands, C C Schwartz
Journal: American Journal of Psychiatry (1978)

The authors explored determinants of psychiatric hospitalization in four Manhattan general hospital emergency rooms and found that although the nature and severity of a patient's problem played the most important role in the decision to hospitalize, the facility involved was also a determining factor. The findings are discussed in relation to policy concerning staffing and organization of emergency room services and future studies of service delivery in this area.
Role of Imaging in Diagnosing and Staging Pancreatic Cancer
Authors: Mahmoud Al-Hawary
Journal: Journal of the National Comprehensive Cancer Network (2016)

Imaging is a key component of diagnosis and staging of pancreatic cancer. CT, MRI, and endoscopic ultrasound are the most used and approved imaging modalities. The updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma feature a recently published Pancreatic Ductal Adenocarcinoma Radiology Reporting Template endorsed by the Society of Abdominal Radiology and the American Pancreatic Association. The goal of the template is to standardize the reporting of the imaging findings and to improve communication among the various team members treating patients with pancreatic cancer, to ensure appropriate patient management.
A Study of Protein Synthesis in Tissue Culture
Authors: Joseph F. Morgan, Maureen A. McCrone
Journal: JNCI Journal of the National Cancer Institute (1957)

Journal Article A Study of Protein Synthesis in Tissue Culture Get access Joseph F. Morgan, Joseph F. Morgan Search for other works by this author on: Oxford Academic PubMed Google Scholar Maureen A. McCrone Maureen A. McCrone Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 19, Issue 3, September 1957, Pages 393–407, https://doi.org/10.1093/jnci/19.3.393 Published: 01 September 1957 Article history Received: 22 April 1957 Published: 01 September 1957
<i>Phaeoacremonium sphinctrophorum</i>as a Novel Agent of Eumycetoma
Authors: Beatriz Bustamante, Sarah Abdalla Ahmed, G. S. De Hoog, Carlos Seas, Wendy W. J. Van De Sande
Journal: JAMA Dermatology (2016)

immobilized side.The lack of movement and stretch appeared to preclude the development of Gottron papules on her paralyzed hand.Therefore, an autoimmune diathesis alone may be insufficient for the development of certain cutaneous DM lesions.Stretch, movement, trauma, and possibly neurogenic inflammation may play a requisite role.Hence, the strikingly unilateral pattern seen in this patient who had experienced a stroke provides clinical insight into the pathophysiologic mechanisms responsible for cutaneous DM.
Re: Patrick C. Walsh, Nathan Lawrentschuk. Immediate Adjuvant Radiation Therapy Following Radical Prostatectomy Should Not Be Advised for Men with Extraprostatic Extension Who Have Negative Surgical Margins. Eur Urol 2016;69:191–2
Authors: Filippo Alongi, Rosario Mazzola, Sergio Fersino
Journal: European Urology (2016)
Beyond the influenza-like illness surveillance: The need for real-time virological data
Authors: J S Casalegno, E Frobert, V Escuret, M Bouscambert-Duchamp, G Billaud, Y Mekki, I Schuffenecker, B Lina, F Morfin, M Valette
Journal: Eurosurveillance (2011)

Preview this article: Beyond the influenza-like illness surveillance: The need for real-time virological data, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/16/1/art19756-en-1.gif
FLT3 Mutation Increases Relapse Risk after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia in First or Second Complete Remission: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
Authors: Abhinav Deol, Salyka Sengsayadeth, Madan Jagasia, Kwang W Ahn, Hailin Wang, Brenda M. Sandmaier, Steven M. Devine, Marcos de Lima, Daniel J. Weisdorf, Wael Saber
Journal: Blood (2014)
Developmental dysplasia of the hip
Authors: M D Sewell, K Rosendahl, D M Eastwood
Journal: BMJ (2009)

People working in healthcare experience grief professionally as well as personally and societally. Attitudinal shifts are needed, argues <b>Lucy Selman</b>, to improve access to formal and informal support and make grief a less lonely experience. Doctors’ openness and willingness to show vulnerability could help
Role of epithelial to mesenchymal transition in hepatocellular carcinoma
Authors: Gianluigi Giannelli, Petra Koudelkova, Francesco Dituri, Wolfgang Mikulits
Journal: Journal of Hepatology (2016)

The epithelial to mesenchymal transition (EMT) is a multistep biological process whereby epithelial cells change in plasticity by transient de-differentiation into a mesenchymal phenotype. EMT and its reversal, mesenchymal to epithelial transition (MET), essentially occur during embryogenetic morphogenesis and have been increasingly described in fibrosis and cancer during the last decade. In carcinoma progression, EMT plays a crucial role in early steps of metastasis when cells lose cell-cell contacts due to ablation of E-cadherin and acquire increased motility to spread into surrounding or distant tissues. Epithelial plasticity has become a hot issue in hepatocellular carcinoma (HCC), as strong inducers of EMT such as transforming growth factor-β are able to orchestrate both fibrogenesis and carcinogenesis, showing rising cytokine levels in cirrhosis and late stage HCC. In this review, we consider the significance of EMT-MET in malignant hepatocytes as well as changes in the plasticity of hepatic stellate cells for cellular heterogeneity of HCC, and further aim at explaining the current limiting insights into EMT by snapshot analyses of HCC tissues. Recent advances in the identification of clinically relevant mechanisms that impinge on important EMT-transcription factors, as well as on miRNAs causing EMT signatures and HCC progression are highlighted. In addition, we draw particular attention to framing EMT in the context of potential clinical relevance for HCC patients. We conclude that some aspects of EMT are still elusive and further studies are required to better link the clinical management of HCC with biomarkers and targeted therapies related to EMT.
NHS Superannuation Scheme
Authors: G W Adams
Journal: BMJ (1977)

to their private or national insurance scheme, and have 75 % of the cost returned to them.It works perfectly well in Ireland and in America.But for heaven's sake let's be honest: 50-60% of my present work is a waste of my time; 20-30% of my patients use me merely as an extension of theNational Insurance Scheme-and successive Govern- ments use us as political pawns and vote- catchers.I like general practice, I like England, and at 36 I do not wish to emigrate.But for my family's sake I cannot just " let things be."Why drive more and more of us away when all that is needed is an honest look at the situation and an honest approach to the prob- lem.
Preclinical Evaluation Of Engineered T Cells In Multiple Myeloma: Uncovering a Mechanism Of Immune Escape
Authors: Zandra K. Klippel, Jeffrey Chou, Andrea M. H. Towlerton, Paul F Robbins, Lilien Voong, William I. Bensinger, H. Lokhorst, Tuna Mutis, Lihua Elizabeth Budde, Edus H. Warren
Journal: Blood (2013)
Abstract P3-03-04: Establishment and characterization of ESR1-mutant breast cancer PDX models
Authors: MJ Wick, E Helman, J Meade, MJ Clark, T Vaught, AW Tolcher, D Rasco, A Patnaik, A Lang, M Beeram, KP Papadopoulos
Journal: Cancer Research (2016)

Abstract The estrogen receptor (ER or ESR1) drives proliferation and growth of luminal type breast cancers. Endocrine therapies are highly effective in a majority of these cancers types; however, disease progression eventually occurs due to acquired resistance resulting in hormone-independent breast cancer. One mechanism of resistance is acquired mutations at codons 537 and 538 in the ligand binding domain of the receptor which are found in ∼12% of pretreated, ER+ patients. These mutations result in constitutive ER activation and hormone-independent progressive disease. Although ESR1 mutated breast cancers are insensitive to endocrine therapy, novel agents targeting these mutations may be effective; however few preclinical models of ESR1-mutant breast cancer are available for preclinical analysis. To this end we have established two patient derived xenograft (PDX) models harboring mutations at codon 537; ST941 with ESR1Y537S and ST1799 with ESR1Y537C. We have characterized these models using genomic analysis and compared with analysis from paired or serially collected clinical tissue and blood. Dependence on estradiol for model growth and sensitivity to endocrine therapies were also evaluated and compared with a hormone-dependent breast cancer models. The ESR1 mutations were not present in primary clinical tissue while several additional mutations were identified including in TP53 and PIK3CA genes. In vivo the ESR1 mutant models grew in the presence or absence of exogenous estradiol and demonstrated reduced sensitivity to endocrine therapies compared with hormone-dependent breast cancer models. ST941 treated with tamoxifen, letrozole or fulvestrant reported moderate tumor growth inhibition versus control while tumor stasis or regressions were reported in MCF-7 and hormone-dependent PDX breast models. Overall we have established and characterized two models of ESR1 mutant breast cancer which can be utilized for development of targeted therapies. Citation Format: Wick MJ, Helman E, Meade J, Clark MJ, Vaught T, Tolcher AW, Rasco D, Patnaik A, Lang A, Beeram M, Papadopoulos KP. Establishment and characterization of ESR1-mutant breast cancer PDX models. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-03-04.
Cytological Studies of Tumors. XXI. A Comparative Ideogram Study of the Yoshida Sarcoma and Its Subline Derivatives&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;3&lt;/xref&gt;
Authors: Sajiro Makino, Motomichi Sasaki
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Cytological Studies of Tumors. XXI. A Comparative Ideogram Study of the Yoshida Sarcoma and Its Subline Derivatives Get access Sajiro Makino, Sajiro Makino Zoological Institute, Hokkaido University, Sapporo, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Motomichi Sasaki Motomichi Sasaki Zoological Institute, Hokkaido University, Sapporo, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 3, March 1958, Pages 465–487, https://doi.org/10.1093/jnci/20.3.465 Published: 01 March 1958 Article history Received: 07 June 1957 Published: 01 March 1958
FDG PET/CT Imaging of Prostate Carcinosarcoma
Authors: Jorge Daniel Oldan, Bennett B. Chin
Journal: Clinical Nuclear Medicine (2016)

We present a case of carcinosarcoma of the prostate. Workup of urinary retention after a previously treated squamous cell carcinoma of the prostate led to a transurethral prostate resection revealing carcinosarcoma of the prostate, which on 18F-FDG PET/CT demonstrated moderate to high avidity of this atypical prostate cancer, with partial obstruction of the urinary system and lung metastases. While FDG PET is not avid for typical prostatic adenocarcinomas, it should be considered for evaluation of atypical prostate cancers.
The Consult Guys - An MI, a Stent, Bleeding, and Surgery! What Do I Do?
Authors: Geno J. Merli, Howard H. Weitz
Journal: Annals of Internal Medicine (2016)

Web Exclusives17 May 2016The Consult Guys - An MI, a Stent, Bleeding, and Surgery! What Do I Do?FREEGeno J. Merli, MD and Howard H. Weitz, MDGeno J. Merli, MDSearch for more papers by this author and Howard H. Weitz, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W16-0005 SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The Consult Guys bring a new perspective to the art and science of medicine with lively discussion and analysis of real-world cases and situations.For more videos from and information on The Consult Guys, visit www.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment Raymond Pierce MDBlack Hills Surgical Hospital19 December 2017 Hospitalist Excellent and MEANINGFUL case Author, Article, and Disclosure InformationAffiliations: Disclosures: Geno J. Merli, MD, reports the following: Research grants/contracts: Bristol-Myers Squibb, Janssen, Portola; Consultancies: Bristol-Myers Squibb, Janssen. Howard H. Weitz, MD, reports that he has no financial relationships or interests to disclose. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCorrection: The Consult Guys - A Real Headache: Anticoagulation and a Subdural Hematoma 17 May 2016Volume 164, Issue 10Page: CG1KeywordsDisclosureHemorrhageResearch grantsResearch reporting guidelinesStent implantationSurgery ePublished: 17 May 2016 Issue Published: 17 May 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.Loading ...
The Novel Human Double Minute (HDM)-2 Inhibitor DS-5272 Is Active Both Alone, and In Combination With Other Novel Agents, Against Multiple Myeloma
Authors: Dongmin Gu, Hua Wang, Zhiqiang Wang, Richard E. Davis, Shengli Cai, Takahiko Seki, Archie Tse, Robert Z. Orlowski
Journal: Blood (2013)
Influenza vaccine effectiveness, 2010/11
Authors: A Steens, W van der Hoek, F Dijkstra, M van der Sande
Journal: Eurosurveillance (2011)

Preview this article: Influenza vaccine effectiveness, 2010/11, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/16/15/art19843-en-1.gif
Abstract PD6-06: Somatic mutation patterns differentially affect survival in breast cancer molecular subtypes
Authors: B Gyorffy, L Pongor, A Szabo, G Bottai, L Pusztai, L Santarpia
Journal: Cancer Research (2016)

Abstract Background: The prognostic effects of somatic gene mutations and correlated gene expression in breast cancer is argument of debate. In this study we analyzed the impact of specific mutations on gene expression and their relevance in the prognosis of breast cancer subtypes. Materials and methods: Exome sequencing and RNA-seq data obtained from TCGA were analyzed. Data was processed using MuTect, MapSplice and RSEM. All together data from 757 patients (ER-/HER2- [n=143], HER2+ including ER positive and negative patients, [n=136], and ER+/HER2- [n=478]) were included. Univariate Receiver Operating Characteristic (ROC) analysis was performed for the top mutated genes (mutated in at least 5% of patients) using the ROC Bioconductor library in R to identify genes whose expression was significantly associated with a mutation. Then, the mean expression of the significant genes was designated as a metagene for each genotype. We assessed the correlation with survival for each metagene by Cox proportional hazards regression and by plotting Kaplan-Meier survival plots. A significance threshold of p&amp;lt;1E-04 was set for each gene to be considered in the survival analysis, and only the top 100 genes were used when there were more than 100 genes significant. Results: In the overall population only few mutated genes including TP53 (HR=1.66), CDH1 (HR=0.61), AKT1 (HR=0.54), ATM (HR=1.76), NF1 (HR=0.58), KMT2D (HR=2.32), and UBR5 (HR=1.94) were significantly associated with survival. In ER-/HER2- mutant samples the PIK3CA (HR=2.79) and MAP3K1 (HR=2.98), and in HER2+ mutant samples the ARID1A (HR=0.26) and PIK3CA (HR=0.27) metagenes were associated with survival, respectively. Overall, using the combined metagene the majority of the significant mutated genes retained their prognostic power. Mutations of specific genes impacted their own expression and prognosis. The expression of TP53 (AUC=0.609, p=2.60E-06), and MAP3K1 (AUC=0.617, p=6.07E-03) was higher in samples with a mutation while the expression of CDH1 (AUC=0.684, p=2.72E-07), PTEN (AUC=0.687, p=1.47E-04), and BRCA1 (AUC=0.608, p=2.24E-02) was lower. Conclusions: Our finding support that specific mutated genes may differentially impact prognosis in breast cancer subtypes. Further efforts are required to understand the biological and prognostic role of specific activating and inactivating mutations across molecular breast cancer subtypes. Citation Format: Gyorffy B, Pongor L, Szabo A, Bottai G, Pusztai L, Santarpia L. Somatic mutation patterns differentially affect survival in breast cancer molecular subtypes. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr PD6-06.